Naptumomab estafenatox
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | 5T4 |
| Clinical data | |
| Identifiers | |
676258-98-3  | |
| None | |
| UNII |
93T929W6LC |
| Chemical data | |
| Formula | C3255H5025N855O1050S18 |
| 73.5 kDa | |
| (what is this?) (verify) | |
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Schematic image of naptumomab estafenatox.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
- ↑ Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S; Lassen, U (2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC 2734423. PMID 19636016.
- ↑ ClinicalTrials.gov
- ↑ WHO Drug Information